中国药物经济学2025，Vol.20Issue(5)：20-25,32,7.DOI:10.12010/j.issn.1673-5846.2025.05.003
基于真实世界数据维格列汀联合二甲双胍治疗2型糖尿病成本-效果分析
Cost-effectiveness Evaluation Of Combination Therapy with Vigliptin and Metformin in the Treatment Of Type 2 Diabetes Mellitus Based on Real World Data
兰奎旭 1唐超 1唐群 1聂晓瑛 2李月云1
作者信息
- 1. 青岛大学附属医院平度院区党政办公室,山东 青岛 266003
- 2. 陕西省康复医院医务部,西安 710065
- 折叠
摘要
Abstract
Objective To scientifically evaluate the long-term cost-effectiveness of vingliptin combined with metformin in the treatment of type 2 diabetes,and provide a reference basis for rational clinical drug use.Methods The Cardiff type 2 diabetes model was used to evaluate the long-term cost-effectiveness of vingliptin combined with metformin compared with acarbose combined with metformin,and a sensitivity analysis was conducted.Results Based on the simulation of the definite mean,it was shown that in the vilagliptin+metformin group,the per capita cost was reduced by 1 013.43 yuan,the per capita cost was increased by 0.038 QALYs,and the incremental cost-effectiveness ratio(ICER)was-26 461.690 yuan/QALY,which had an absolute advantage.Based on individual data simulation,it shows that in the vilagliptin+metformin group,the per capita increase in cost was 27 472.926 yuan,and the per capita increase was 0.978 QALYs.The ICER was 28 095.540 yuan/QALY,which was lower than twice the per capita GDP of China in 2021(80 976 yuan),and had an economic advantage.The results of the sensitivity analysis were consistent with those of the basic analysis.Conclusion In the long-term treatment of type 2 diabetes Mellitus,vilagliptin+metformin treatment has economic advantages and should be recommended preferentially in clinical application.关键词
维格列汀/卡迪夫2型糖尿病模型/真实世界数据/2型糖尿病Key words
Vigliptin/Cardiff type 2 diabetes model/Real-world data/Type 2 diabetes mellitus分类
医药卫生引用本文复制引用
兰奎旭,唐超,唐群,聂晓瑛,李月云..基于真实世界数据维格列汀联合二甲双胍治疗2型糖尿病成本-效果分析[J].中国药物经济学,2025,20(5):20-25,32,7.
